Maharashtra Herald

Cold Agglutinin Disease Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type

 Breaking News
  • No posts were found

Cold Agglutinin Disease Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type

March 13
20:45 2023
Cold Agglutinin Disease Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type

DelveInsight’s, “Cold Agglutinin Disease Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Cold Agglutinin Disease pipeline landscape. It covers the Cold Agglutinin Disease pipeline drug profiles, including Cold Agglutinin Disease clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Cold Agglutinin Disease Emerging drugs, the Cold Agglutinin Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Cold Agglutinin Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Cold Agglutinin Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Cold Agglutinin Disease clinical trials studies, Cold Agglutinin Disease NDA approvals (if any), and product development activities comprising the technology, Cold Agglutinin Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Cold Agglutinin Disease Pipeline Report

 

  • DelveInsight’s Cold Agglutinin Disease Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.

 

  • The leading Cold Agglutinin Disease Companies include Bioverativ, Novartis Pharmaceuticals, and others.

 

  • Promising Cold Agglutinin Disease Pipeline Therapies includes Sutimlimab, APL-2, Bortezomib, and others.

 

  • The Cold Agglutinin Disease Companies and academics are working to assess challenges and seek opportunities that could influence Cold Agglutinin Disease R&D. The Cold Agglutinin Disease pipeline therapies under development are focused on novel approaches to treat/improve Cold Agglutinin Disease.

 

Request a sample and discover the recent breakthroughs happening in the Cold Agglutinin Disease Pipeline landscape @ Cold Agglutinin Disease Pipeline Outlook Report

 

Cold Agglutinin Disease Overview

Cold agglutinin disease (CAD) is a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). Autoimmune diseases occur when one’s own immune system attacks healthy tissue. More specifically, CAD is a subtype of autoimmune hemolytic anemia. In this type of disorder, red blood cells are “tagged” by antibodies and are then destroyed by other types of immune cells. The disease is termed “cold” because the antibodies are active and cause hemolysis at cold temperatures, usually 3 to 4oC (37 to 39oF), which is not necessarily the case in other types of autoimmune hemolytic anemia.

 

Cold Agglutinin Disease Emerging Drugs Profile

 

  • BIVV020: Bioverativ

BIVV020 is a humanized monoclonal antibody that targets complement C1s. A phase 1b clinical trial that was testing the safety and tolerability of the experimental drug BIVV020 in adult patients with cold agglutinin disease (CAD) has been completed. The primary objective of the trial was to assess the safety and tolerability of the treatment as measured by the number of participants with adverse events. Secondary objectives were the effect of the treatment on complement-mediated hemolysis, as well as its pharmacodynamics, pharmacokinetics, and immunogenicity. The drug is being developed by Bioverativ, a Sanofi company.

 

  • Iptacopan: Novartis Pharmaceuticals

Iptacopan is an oral investigational therapy by Novartis. It is a first-in-class, potent, and highly selective factor B inhibitor of the alternative complement pathway. It binds to factor B and suppresses the activity of C3 convertase. This way, signaling from the alternative complement pathway and the activation of the amplification loop are also suppressed. This inhibits the generation of the downstream C5 convertase complex, opsonization, and the formation of C3a and C5a anaphylatoxins and membrane attack complex. Because the direct classical and lectin pathway signaling remains intact, the risk of meningococcal infection is lower with Iptacopan compared to terminal complement pathway inhibitors. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cold Agglutinin Disease.

 

For further information, refer to the detailed Cold Agglutinin Disease Drugs Launch, Cold Agglutinin Disease Developmental Activities, and Cold Agglutinin Disease News, click here for Cold Agglutinin Disease Ongoing Clinical Trial Analysis

 

Cold Agglutinin Disease Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Cold Agglutinin Disease. The companies which have their Cold Agglutinin Disease drug candidates in the most advanced stage, i.e. phase II include, Novartis Pharmaceuticals.

 

Cold Agglutinin Disease Pipeline Segmentation

 

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Find out more about the Cold Agglutinin Disease Pipeline Segmentation, Therapeutics Assessment, and Cold Agglutinin Disease Emerging Drugs @ Cold Agglutinin Disease Treatment Landscape

 

Scope of the Cold Agglutinin Disease Pipeline Report

 

  • Coverage- Global 

 

  • Cold Agglutinin Disease Companies- Bioverativ, Novartis Pharmaceuticals, and others.

 

  • Cold Agglutinin Disease Pipeline Therapies- Sutimlimab, APL-2, Bortezomib, and others.

 

  • Cold Agglutinin Disease Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Cold Agglutinin Disease Pipeline Companies and Therapies, click here @ Cold Agglutinin Disease Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Cold Agglutinin Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cold Agglutinin Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name : Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Iptacopan: Novartis Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. BIVV020: Bioverativ
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cold Agglutinin Disease Key Companies
  21. Cold Agglutinin Disease Key Products
  22. Cold Agglutinin Disease- Unmet Needs
  23. Cold Agglutinin Disease- Market Drivers and Barriers
  24. Cold Agglutinin Disease- Future Perspectives and Conclusion
  25. Cold Agglutinin Disease Analyst Views
  26. Cold Agglutinin Disease Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Cold Agglutinin Disease Mergers and acquisitions, Cold Agglutinin Disease Licensing Activities @ Cold Agglutinin Disease Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/